Biomedical nanotechnology : methods and protocols / edited by Sarah J. Hurst.
Contributor(s): Hurst, Sarah J [editor]
.
Material type: 












Item type | Current location | Call number | Copy number | Status | Date due | Item holds |
---|---|---|---|---|---|---|
![]() |
Biblioteca del Campus | 620.5 H9668b 2011 (Browse shelf) | Ej. 1 | Available |
Includes indexes (pages 431-434).
Includes bibliographical references.
Biomedical nanotechnology -- Part I. Using nanomaterials in sesing, imaging, and therapeutics -- 2 Multiplexed detection of oligonucleotides with biobarcoded gold nanoparticle probes -- 3 Molecular detection of biomarkers and cells using magnetic nanoparticles and diagnostic magnetic resonance -- 4 Real-time quantum dot tracking of single proteins -- 5 Titanium dioxide nanoparticles in advanced imaging and nanotherapeutics -- 6 Surface modification and biomolecule immobilization on polymer spheres or biosensing applications -- Multivalent conjugation of peptides, proteins, and DNA to semiconductor quantum dots -- 8 Single snO2 nanowire-based microelectrode -- 9 Biosensing using nanoelectromechanical systems -- 10 Nano "Fly Paper"; technology for the capture of circulating tumor cells -- 11 Polymeric nanoparticles for photodynamic therapy -- 12 Hydrogel templates for the fabrication of homogeneous polymer microparticles -- 13 Antibacterial application of engineered bacteriophage nanomedicines : antibody-targeted, chloramphenicol prodrug loaded bacteriophages for inhibiting the growth of staphylococcus aureus bacteria -- 14 Viruses as nanomaterials for drug delivery -- 15 Applications of carbon nanotubes in biomedical studies -- 16 Electrospun nanofibrous scaffolds for engineering soft connective tissues -- 17 Peptide amphiphiles and porous biodegradable scaffolds for tissue regeneration in the brain and spinal cord -- 18 Computational simulations of the interaction of lipid membranes with DNA-functionalized gold nanoparticles -- 19 Cytotoxic assessment of carbon nanotube interaction with cell cultures -- 20 Nanoparticle toxicology : measurements of pulmonary hazard effects following exposures to nanoparticles -- 21 Nanoparticle therapeutics : FDA approval, clinical trials, regulatory pathways, and case study -- 22 Legislating the laboratory? Promotion and precaution in a nanomaterials company -- 23 Navigating the patent landscapes for nanotechnology : english gardens or tangled grounds -- 24 Scientific entrepreneurship in the materials and life science industries -- 25 Applying the marketing mix (5 Ps) to bionanotechnology -- 26 Managing the "Known Unknowns"; : theranostic cancer nanomedicine and informed consent.
There are no comments for this item.